Drug research

NAL ER

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Nalbuphine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)NCT07671924	Trevi Therapeutics	Phase 2	Recruiting	2027-09Estimated
Cough Reduction in IPF With Nalbuphine ERNCT05964335	Trevi Therapeutics	Phase 2	Completed	2025-04-24Actual
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughNCT04030026	Trevi Therapeutics	Phase 2	Completed	2022-05-27Actual
Refractory Chronic Cough Improvement Via NAL ER (RIVER)NCT05962151	Trevi Therapeutics	Phase 2	Completed	2025-01-06Actual
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsNCT07671911	Trevi Therapeutics	Phase 3	Recruiting	2028-06Estimated

Trevi TherapeuticsRecruitingPrimary completion: 2027-09 · Estimated

Trial details

Trevi TherapeuticsCompletedPrimary completion: 2025-04-24 · Actual

Trial details

Trevi TherapeuticsCompletedPrimary completion: 2022-05-27 · Actual

Trial details

Trevi TherapeuticsCompletedPrimary completion: 2025-01-06 · Actual

Trial details

Trevi TherapeuticsRecruitingPrimary completion: 2028-06 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.